SHL Telemedicine (NASDAQ:SHLT) and Auna (NYSE:AUNA) Critical Contrast

SHL Telemedicine (NASDAQ:SHLT) and Auna (NYSE:AUNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Valuation and Earnings

This table compares SHL Telemedicine and Auna”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SHL Telemedicine	$55.94 million	0.60	-$7.06 million	N/A	N/A
Auna	$4.39 billion	0.12	-$67.90 million	$0.38	18.13

SHL Telemedicine has higher earnings, but lower revenue than Auna.

Analyst Recommendations

This is a summary of current ratings and target prices for SHL Telemedicine and Auna, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SHL Telemedicine	0	0	0	0	0.00
Auna	0	0	1	0	3.00

Auna has a consensus price target of $13.50, indicating a potential upside of 95.94%. Given Auna’s stronger consensus rating and higher probable upside, analysts clearly believe Auna is more favorable than SHL Telemedicine.

Volatility & Risk

SHL Telemedicine has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Auna has a beta of 3.2, indicating that its share price is 220% more volatile than the S&P 500.

Profitability

This table compares SHL Telemedicine and Auna’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SHL Telemedicine	N/A	N/A	N/A
Auna	N/A	N/A	N/A

Insider & Institutional Ownership

20.1% of SHL Telemedicine shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Auna beats SHL Telemedicine on 5 of the 8 factors compared between the two stocks.

About SHL Telemedicine

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.

About Auna

Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.